Cholesterol accumulation by solid tumors was noted a hundred years ago.
(2010) [2]:
"We have identified metabolites associated with PCa metastasis and specifically identified high levels of cholesterol in PCa bone metastases. Based on our findings and the previous literature, this makes cholesterol a possible therapeutic target for advanced PCa."
(2013) [3]:
"... normal prostate epithelial cells have an abnormally high cholesterol content, with cholesterol levels increasing further during progression to PCa. In this review, we explore why and how this occurs."
"Perturbations in cholesterol homeostasis appear to be maintained even when PCa approaches the advanced, 'castration-resistant' state. Overall, this provides a link between cholesterol accumulation and PCa cell growth. Given there is currently no cure for castration-resistant PCa, could cholesterol metabolism be a novel target for PCa therapy?"
***
New paper:
"Higher intratumoral cholesterol synthesis is associated with a worse prognosis in prostate cancer."
"The vitamin D-regulated enzyme sterol-27-hydroxylase (CYP27A1) converts cholesterol to 27-hydroxycholesterol, potentially lowering intracellular cholesterol levels. We hypothesized that low CYP27A1 expression is associated with high cholesterol synthesis, low vitamin D signaling, and higher risk of lethal prostate cancer."
"CYP27A1 expression was lower in tumors with higher Gleason grade and higher expression of cholesterol synthesis enzymes ..."
"Lower CYP27A1 was associated with higher risk of lethal cancer ..."
"These observations further support the hypothesis that intratumoral cholesterol accumulation through higher synthesis and decreased catabolism is a feature of lethal prostate cancer."
Cancer Epidemiol Biomarkers Prev. 2019 Mar 13. pii: cebp.1083.2018. doi: 10.1158/1055-9965.EPI-18-1083. [Epub ahead of print]
Intratumoral sterol-27-hydroxylase (CYP27A1) expression in relation to cholesterol synthesis and vitamin D signaling and its association with lethal prostate cancer.
Memorial Sloan Kettering Cancer Center stopsack@mskcc.org.
3
Centre for Cancer Research and Cell Biology, Queen's University Belfast.
4
Cancer Epidemiology, Moffitt Cancer Center.
5
Department of Nutrition, Harvard T.H. Chan School of Public Health.
6
Department of Epidemiology, Harvard TH Chan School of Public Health.
7
Department of Medicine, Memorial Sloan Kettering Cancer Center.
Abstract
BACKGROUND:
Higher intratumoral cholesterol synthesis is associated with a worse prognosis in prostate cancer. The vitamin D-regulated enzyme sterol-27-hydroxylase (CYP27A1) converts cholesterol to 27-hydroxycholesterol, potentially lowering intracellular cholesterol levels. We hypothesized that low CYP27A1 expression is associated with high cholesterol synthesis, low vitamin D signaling, and higher risk of lethal prostate cancer.
METHODS:
In 404 patients from the prospective prostate cancer cohorts within the Health Professionals Follow-up Study (HPFS) and the Physicians' Health Study (PHS), we assessed intratumoral CYP27A1 expression and proxies of cholesterol synthesis using transcriptome profiling, prediagnostic plasma 25-hydroxyvitamin D (25(OH)D, n = 132) and intratumoral vitamin D receptor protein expression (VDR, n = 300). Patients were followed for metastases and prostate cancer mortality (lethal cancer; median follow-up, 15.3 years).
RESULTS:
CYP27A1 expression was lower in tumors with higher Gleason grade and higher expression of cholesterol synthesis enzymes including the second rate-limiting enzyme, SQLE. We did not detect consistent associations between CYP27A1 and 25(OH)D, VDR, or CYP24A1 mRNA expression. Lower CYP27A1 was associated with higher risk of lethal cancer in both cohorts, independent of SQLE (adjusted odds ratio for lowest vs. highest quartile of CYP27A1, 2.64; 95% CI, 1.24-5.62). This association was attenuated when additionally adjusting for Gleason grade (odds ratio, 1.76; 95% CI, 0.75-4.17).
CONCLUSIONS:
Low CYP27A1 expression was associated with higher cholesterol synthesis and a higher risk of lethal disease.
IMPACT:
These observations further support the hypothesis that intratumoral cholesterol accumulation through higher synthesis and decreased catabolism is a feature of lethal prostate cancer.
And since (other than what we make ourselves) cholesterol only comes from animal sources??? How effective would a plant-based, no-meat/no-dairy diet be?? Eat Well - cujoe
That's the diet I switched to beginning of 2019 but from what I gathered from a previous post is that if you take away their cholesterol, they'll make their own, hence the addition of a statin.
Well, if nothing else, at least it makes the little devils work harder to survive. I'm due for a 3 mo appt next week, I will see if my MO has anything to say about statins? Thanks for the suggestion, IT. Be Well - cujoe
Unless I looked like Andre the Giant, my Doc wouldn't give me a script for a statin. I've asked him before and he said the studies don't support the use of them for Pca. I've taken a good quality Red Yeast Rice supplement for over a year now but I've never had elevated cholesterol in my life- no idea if it's helpful in slowing progression.
Well, my theory is that the three things that most drive PCa are: cholesterol, inflammation, and glycolysis. So, I've modified my diet, stay physically active, eliminated all sources of stress, and take a wide range of supplements and plant powders that help with one or more of these three issues. So far, I'm beating the odds. However, as many of us are running our own personal clinical trials, time will be the true arbiter of what does/does not work - Good Luck & Good Health - cujoe
Get another doctor! I don't need it but I take the lowest dose of Atorvastatin, 10 mg. Grapefruit are to be avoided when taking Atorvastatin. I also take 500 mg of Metformin 2X daily. I have a forward thinking doctor involved in my care. He has added low dose Naltrexone to my regimen.
I have been vegan for over a year. Read about Ruth Heidrich.
For decades we were told to avoid eggs. Eventually we learned that a breakfast egg does not meaningfully affect cholesterol levels. The body needs cholesterol & does not rely on diet. The brain has a massive concentration of the stuff. It's needed for steroidogenesis. Etc.
I hate to do it, but highest-dose statin (or comparable drug, perhaps) is essential IMO.
You understanding of the biochemistry of cancer is much, MUCH wider and deeper than mine, but I'm going to err on the side of "less is more" when it comes to all dietary sources of cholesterol. Be Well - cujoe
The statin effect is reportedly dose-related. I take 40 mg Simvastatin. I wish I had started when the upper dose was 80 mg. Men on that were grandfathered. Crazy that they did not introduce a 60 mg when they lowered it.
Perhaps the max dose of another brand would deliver more benefit?
Some doubt has recently been cast on the idea that statins can actually affect PCa production. To me, this makes little sense, since the cells would then make all they need if deprived of circulating cholesterol. What would be the point of lowering blood supplies if the cells could replace the shortfall.
As with Metformin, one must remember that PCa studies are mostly based on men who are using the drug for non-PCa reasons. That makes it unlikely that the populations studied would have included men who started with low cholesterol.
However, since benefits seem to be based on dosage, rather than target blood levels, I'm sticking to the highest dose.
My husband's total was/is low normal and LDL normal. The cardiologist put him on 80 mg arovastatinto fight back the LDL from ADT...he thinks the acceleration of CVD one needs to use higher dose of statin to fight against it.
Nice that near the end of the video an email from within the egg industry acknowledges that the choline in eggs may promote cancer progression. There author of the email expressed some concern as to how much press the study would get. I stopped the video to read what was on the screen. Hmm? Negative press has an impact on profit correct? Once upon a time cholesterol made a negative impact on the egg industry. At the time cholesterol was deemed to be "bad" a large percentage of us had two eggs for breakfast. Then eggs were good for us again.
Although I am now a vegan, I would like to see a study done with eggs laid by free range, non GMO fed chickens that are allowed to do "chicken things" such as scratch around in the dirt for bugs and worms and have chicks. Would the eggs laid by chickens that have "normal stresses" in their lives by living on small farms produce a healthier egg for human consumption?
Grass fed, free range cattle's flesh is a source of conjugated linoleic acid, which inhibits cancer. The flesh of the regular USDA beef raised in pens and fed corn has more omega 6's than the free range.
I add a little RAW wheat germ to a blended drink I make for plant based choline.
I am on low dose (10 mg) atorvastatin. I asked my PCP to increase the dose, mentioning that it is useful in the fight against prostate cancer. He refused, saying that my lab results were fine. It's like he didn't even hear what I said about PC and statins. At an earlier visit he refused to consider prescribing metformin. Time to find a different doctor?
It seems to me that an abundance of caution should be exercised by all of us in interpreting such studies and articles. There does not seem to be a clear correlation between "cholesterol" and PCa directly. It may be how our bodies use and/or produce the various amino acids, cholesterol, and hormone precursors, etc. once PCa is present.
I have yet to find PCa to be a simple or static disease. It is a complex and adaptable one that mutates as required to survive and seems quite capable of producing what it needs or diverting what it needs from other parts of the body. Where's a silver bullet when you need one!
"In summary, prostate cancers that progress to lethal disease rely on de novo cholesterol synthesis (via SQLE), rather than transcellular uptake (via LDLR) or cholesterol esterification (via SOAT1)."
"Lethal prostate cancers have higher expression of squalene monooxygenase (SQLE), the second rate-limiting enzyme of cholesterol synthesis. Preclinical studies suggested that aberrant cholesterol regulators, receptors and transporters contribute to cholesterol accumulation uniformly. We assessed their association with features of aggressive cancers. In the prospective prostate cancer cohorts within the Health Professional Follow-up Study, the Physicians’ Health Study and the Swedish Watchful Waiting Study, tumor mRNA expression profiling was performed. Lethal disease was defined as mortality or metastases from prostate cancer (n = 266) in contrast to non-lethal disease without metastases after >8 years of follow-up (n = 476). Associations with Gleason grade were additionally assessed using The Cancer Genome Atlas primary prostate cancer dataset (n = 333). Higher Gleason grade was associated with lower LDLR expression, lower SOAT1 and higher SQLE expression. Besides high SQLE expression, cancers that became lethal despite primary treatment were characterized by low LDLR expression (odds ratio for highest versus lowest quintile, 0.37; 95% CI 0.18–0.76) and by low SOAT1 expression (odds ratio, 0.41; 95% CI 0.21–0.83). The association of LDLR expression and lethality was not present in tumors with high IDOL expression. ABCA1, PCSK9 or SCARB1 expressions were not associated with Gleason grade or lethal cancer. In summary, prostate cancers that progress to lethal disease rely on de novo cholesterol synthesis (via SQLE), rather than transcellular uptake (via LDLR) or cholesterol esterification (via SOAT1). These results may help design pharmacotherapy for high-risk patients."
If I'm reading the extract correctly it seems tobe referencing the Warburg effect and that cancer cells use anaerobic metabolism to consume glucose hence the benefits of Metformin and Statins to reduce circulating glucose levels as detailed in Preface to the Second Revised German Edition of
...and detailed article below in a very long read.
In the early 20th century, the German biochemist Otto Warburg believed that tumors could be treated by disrupting their source
of energy.
BY SAM APPLE
MAY 12, 2016
The story of modern cancer research begins, somewhat improbably, with the sea urchin. In the first decade of the 20th century, the German biologist Theodor Boveri discovered that if he fertilized sea-urchin eggs with two sperm rather than one, some of the cells would end up with the wrong number of chromosomes and fail to develop properly. It was the era before modern genetics, but Boveri was aware that cancer cells, like the deformed sea urchin cells, had abnormal chromosomes; whatever caused cancer, he surmised, had something to do with chromosomes.
Today Boveri is celebrated for discovering the origins of cancer, but another German scientist, Otto Warburg, was studying sea-urchin eggs around the same time as Boveri. His research, too, was hailed as a major breakthrough in our understanding of cancer. But in the following decades, Warburg’s discovery would largely disappear from the cancer narrative, his contributions considered so negligible that they were left out of textbooks altogether.
Unlike Boveri, Warburg wasn’t interested in the chromosomes of sea-urchin eggs. Rather, Warburg was focused on energy, specifically on how the eggs fueled their growth. By the time Warburg turned his attention from sea-urchin cells to the cells of a rat tumor, in 1923, he knew that sea-urchin eggs increased their oxygen consumption significantly as they grew, so he expected to see a similar need for extra oxygen in the rat tumor. Instead, the cancer cells fueled their growth by swallowing up enormous amounts of glucose (blood sugar) and breaking it down without oxygen. The result made no sense. Oxygen-fueled reactions are a much more efficient way of turning food into energy, and there was plenty of oxygen available for the cancer cells to use. But when Warburg tested additional tumors, including ones from humans, he saw the same effect every time. The cancer cells were ravenous for glucose.
Warburg’s discovery, later named the Warburg effect, is estimated to occur in up to 80 percent of cancers. It is so fundamental to most cancers that a positron emission tomography (PET) scan, which has emerged as an important tool in the staging and diagnosis of cancer, works simply by revealing the places in the body where cells are consuming extra glucose. In many cases, the more glucose a tumor consumes, the worse a patient’s prognosis.
In the years following his breakthrough, Warburg became convinced that the Warburg effect occurs because cells are unable to use oxygen properly and that this damaged respiration is, in effect, the starting point of cancer. Well into the 1950s, this theory — which Warburg believed in until his death in 1970 but never proved — remained an important subject of debate within the field. And then, more quickly than anyone could have anticipated, the debate ended. In 1953, James Watson and Francis Crick pieced together the structure of the DNA molecule and set the stage for the triumph of molecular biology’s gene-centered approach to cancer. In the following decades, scientists came to regard cancer as a disease governed by mutated genes, which drive cells into a state of relentless division and proliferation. The metabolic catalysts that Warburg spent his career analyzing began to be referred to as “housekeeping enzymes” — necessary to keep a cell going but largely irrelevant to the deeper story of cancer.
“It was a stampede,” says Thomas Seyfried, a biologist at Boston College, of the move to molecular biology. “Warburg was dropped like a hot potato.” There was every reason to think that Warburg would remain at best a footnote in the history of cancer research. (As Dominic D’Agostino, an associate professor at the University of South Florida Morsani College of Medicine, told me, “The book that my students have to use for their cancer biology course has no mention of cancer metabolism.”) But over the past decade, and the past five years in particular, something unexpected happened: Those housekeeping enzymes have again become one of the most promising areas of cancer research. Scientists now wonder if metabolism could prove to be the long-sought “Achilles’ heel” of cancer, a common weak point in a disease that manifests itself in so many different forms.
There are typically many mutations in a single cancer. But there are a limited number of ways that the body can produce energy and support rapid growth. Cancer cells rely on these fuels in a way that healthy cells don’t. The hope of scientists at the forefront of the Warburg revival is that they will be able to slow — or even stop — tumors by disrupting one or more of the many chemical reactions a cell uses to proliferate, and, in the process, starve cancer cells of the nutrients they desperately need to grow.
Even James Watson, one of the fathers of molecular biology, is convinced that targeting metabolism is a more promising avenue in current cancer research than gene-centered approaches. At his office at the Cold Spring Harbor Laboratory in Long Island, Watson, 88, sat beneath one of the original sketches of the DNA molecule and told me that locating the genes that cause cancer has been “remarkably unhelpful” — the belief that sequencing your DNA is going to extend your life “a cruel illusion.” If he were going into cancer research today, Watson said, he would study biochemistry rather than molecular biology.
“I never thought, until about two months ago, I’d ever have to learn the Krebs cycle,” he said, referring to the reactions, familiar to most high-school biology students, by which a cell powers itself. “Now I realize I have to.”
Born in 1883 into the illustrious Warburg family, Otto Warburg was raised to be a science prodigy. His father, Emil, was one of Germany’s leading physicists, and many of the world’s greatest physicists and chemists, including Albert Einstein and Max Planck, were friends of the family. (When Warburg enlisted in the military during World War I, Einstein sent him a letter urging him to come home for the sake of science.) Those men had explained the mysteries of the universe with a handful of fundamental laws, and the young Warburg came to believe he could bring that same elegant simplicity and clarity to the workings of life. Long before his death, Warburg was considered perhaps the greatest biochemist of the 20th century, a man whose research was vital to our understanding not only of cancer but also of respiration and photosynthesis. In 1931 he won the Nobel Prize for his work on respiration, and he was considered for the award on two other occasions — each time for a different discovery. Records indicate that he would have won in 1944, had the Nazis not forbidden the acceptance of the Nobel by German citizens.
That Warburg was able to live in Germany and continue his research throughout World War II, despite having Jewish ancestry and most likely being gay, speaks to the German obsession with cancer in the first half of the 20th century. At the time, cancer was more prevalent in Germany than in almost any other nation. According to the Stanford historian Robert Proctor, by the 1920s Germany’s escalating cancer rates had become a “major scandal.” A number of top Nazis, including Hitler, are believed to have harbored a particular dread of the disease; Hitler and Joseph Goebbels took the time to discuss new advances in cancer research in the hours leading up to the Nazi invasion of the Soviet Union. Whether Hitler was personally aware of Warburg’s research is unknown, but one of Warburg’s former colleagues wrote that several sources told him that “Hitler’s entourage” became convinced that “Warburg was the only scientist who offered a serious hope of producing a cure for cancer one day.”
Although many Jewish scientists fled Germany during the 1930s, Warburg chose to remain. According to his biographer, the Nobel Prize-winning biochemist Hans Krebs, who worked in Warburg’s lab, “science was the dominant emotion” of Warburg’s adult life, “virtually subjugating all other emotions.” In Krebs’s telling, Warburg spent years building a small team of specially trained technicians who knew how to run his experiments, and he feared that his mission to defeat cancer would be set back significantly if he had to start over. But after the war, Warburg fired all the technicians, suspecting that they had reported his criticisms of the Third Reich to the Gestapo. Warburg’s reckless decision to stay in Nazi Germany most likely came down to his astonishing ego. (Upon learning he had won the Nobel Prize, Warburg’s response was, “It’s high time.”)
“Modesty was not a virtue of Otto Warburg,” says George Klein, a 90-year-old cancer researcher at the Karolinska Institute in Sweden. As a young man, Klein was asked to send cancer cells to Warburg’s lab. A number of years later, Klein’s boss approached Warburg for a recommendation on Klein’s behalf. “George Klein has made a very important contribution to cancer research,” Warburg wrote. “He has sent me the cells with which I have solved the cancer problem.” Klein also recalls the lecture Warburg gave in Stockholm in 1950 at the 50th anniversary of the Nobel Prize. Warburg drew four diagrams on a blackboard explaining the Warburg effect, and then told the members of the audience that they represented all that they needed to know about the biochemistry of cancer.
Warburg was so monumentally stubborn that he refused to use the word “mitochondria,” even after it had been widely accepted as the name for the tiny structures that power cells. Instead Warburg persisted in calling them “grana,” the term he came up with when he identified those structures as the site of cellular respiration. Few things would have been more upsetting to him than the thought of Nazi thugs chasing him out of the beautiful Berlin institute, modeled after a country manor and built specifically for him. After the war, the Russians approached Warburg and offered to erect a new institute in Moscow. Klein recalls that Warburg told them with great pride that both Hitler and Stalin had failed to move him. As Warburg explained to his sister: “Ich war vor Hitler da” — “I was here before Hitler.”
Imagine two engines, the one being driven by complete and the other by incomplete combustion of coal,” Warburg wrote in 1956, responding to a criticism of his hypothesis that cancer is a problem of energy. “A man who knows nothing at all about engines, their structure and their purpose may discover the difference. He may, for example, smell it.”
The “complete combustion,” in Warburg’s analogy, is respiration. The “incomplete combustion,” turning nutrients into energy without oxygen, is known as fermentation. Fermentation provides a useful backup when oxygen can’t reach cells quickly enough to keep up with demand. (Our muscle cells turn to fermentation during intense exercise.) Warburg thought that defects prevent cancer cells from being able to use respiration, but scientists now widely agree that this is wrong. A growing tumor can be thought of as a construction site, and as today’s researchers explain it, the Warburg effect opens the gates for more and more trucks to deliver building materials (in the form of glucose molecules) to make “daughter” cells.
If this theory can explain the “why” of the Warburg effect, it still leaves the more pressing question of what, exactly, sets a cell on the path to the Warburg effect and cancer. Scientists at several of the nation’s top cancer hospitals have spearheaded the Warburg revival, in hopes of finding the answer. These researchers, typically molecular biologists by training, have turned to metabolism and the Warburg effect because their own research led each of them to the same conclusion: A number of the cancer-causing genes that have long been known for their role in cell division also regulate cells’ consumption of nutrients.
Craig Thompson, the president and chief executive of the Memorial Sloan Kettering Cancer Center, has been among the most outspoken proponents of this renewed focus on metabolism. In Thompson’s analogy, the Warburg effect can be thought of as a social failure: a breakdown of the nutrient-sharing agreement that single-celled organisms signed when they joined forces to become multicellular organisms. His research showed that cells need to receive instructions from other cells to eat, just as they require instructions from other cells to divide. Thompson hypothesized that if he could identify the mutations that lead a cell to eat more glucose than it should, it would go a long way toward explaining how the Warburg effect and cancer begin. But Thompson’s search for those mutations didn’t lead to an entirely new discovery. Instead, it led him to AKT, a gene already well known to molecular biologists for its role in promoting cell division. Thompson now believes AKT plays an even more fundamental role in metabolism.
The protein created by AKT is part of a chain of signaling proteins that is mutated in up to 80 percent of all cancers. Thompson says that once these proteins go into overdrive, a cell no longer worries about signals from other cells to eat; it instead stuffs itself with glucose. Thompson discovered he could induce the “full Warburg effect” simply by placing an activated AKT protein into a normal cell. When that happens, Thompson says, the cells begin to do what every single-celled organism will do in the presence of food: eat as much as it can and make as many copies of itself as possible. When Thompson presents his research to high-school students, he shows them a slide of mold spreading across a piece of bread. The slide’s heading — “Everyone’s first cancer experiment” — recalls Warburg’s observation that cancer cells will carry out fermentation at almost the same rate of wildly growing yeasts.
Just as Thompson has redefined the role of AKT, Chi Van Dang, director of the Abramson Cancer Center at the University of Pennsylvania, has helped lead the cancer world to an appreciation of how one widely studied gene can profoundly influence a tumor’s metabolism. In 1997, Dang became one of the first scientists to connect molecular biology to the science of cellular metabolism when he demonstrated that MYC — a so-called regulator gene well known for its role in cell proliferation — directly targets an enzyme that can turn on the Warburg effect. Dang recalls that other researchers were skeptical of his interest in a housekeeping enzyme, but he stuck with it because he came to appreciate something critical: Cancer cells can’t stop eating.
Unlike healthy cells, growing cancer cells are missing the internal feedback loops that are designed to conserve resources when food isn’t available. They’re “addicted to nutrients,” Dang says; when they can’t consume enough, they begin to die. The addiction to nutrients explains why changes to metabolic pathways are so common and tend to arise first as a cell progresses toward cancer: It’s not that other types of alterations can’t arise first, but rather that, when they do, the incipient tumors lack the access to the nutrients they need to grow. Dang uses the analogy of a work crew trying to put up a building. “If you don’t have enough cement, and you try to put a lot of bricks together, you’re going to collapse,” he says. .
Metabolism-centered therapies have produced some tantalizing successes. Agios Pharmaceuticals, a company co-founded by Thompson, is now testing a drug that treats cases of acute myelogenous leukemia that have been resistant to other therapies by inhibiting the mutated versions of the metabolic enzyme IDH 2. In clinical trials of the Agios drug, nearly 40 percent of patients who carry these mutations are experiencing at least partial remissions.
Researchers working in a lab run by Peter Pedersen, a professor of biochemistry at Johns Hopkins, discovered that a compound known as 3-bromopyruvate can block energy production in cancer cells and, at least in rats and rabbits, wipe out advanced liver cancer. (Trials of the drug have yet to begin.) At Penn, Dang and his colleagues are now trying to block multiple metabolic pathways at the same time. In mice, this two-pronged approach has been able to shrink some tumors without debilitating side effects. Dang says the hope is not necessarily to find a cure but rather to keep cancer at bay in a “smoldering quiet state,” much as patients treat their hypertension.
Warburg, too, appreciated that a tumor’s dependence upon a steady flow of nutrients might eventually prove to be its fatal weakness. Long after his initial discovery of the Warburg effect, he continued to research the enzymes involved in fermentation and to explore the possibility of blocking the process in cancer cells. The challenge Warburg faced then is the same one that metabolism researchers face today: Cancer is an incredibly persistent foe. Blocking one metabolic pathway has been shown to slow down and even stop tumor growth in some cases, but tumors tend to find another way. “You block glucose, they use glutamine,” Dang says, in reference to another primary fuel used by cancers. “You block glucose and glutamine, they might be able to use fatty acids. We don’t know yet.”
Given Warburg’s own story of historical neglect, it’s fitting that what may turn out to be one of the most promising cancer metabolism drugs has been sitting in plain sight for decades. That drug, metformin, is already widely prescribed to decrease the glucose in the blood of diabetics (76.9 million metformin prescriptions were filled in the United States in 2014). In the years ahead, it’s likely to be used to treat — or at least to prevent — some cancers. Because metformin can influence a number of metabolic pathways, the precise mechanism by which it achieves its anticancer effects remains a source of debate. But the results of numerous epidemiological studies have been striking. Diabetics taking metformin seem to be significantly less likely to develop cancer than diabetics who don’t — and significantly less likely to die from the disease when they do.
Near the end of his life, Warburg grew obsessed with his diet. He believed that most cancer was preventable and thought that chemicals added to food and used in agriculture could cause tumors by interfering with respiration. He stopped eating bread unless it was baked in his own home. He would drink milk only if it came from a special herd of cows, and used a centrifuge at his lab to make his cream and butter.
Warburg’s personal diet is unlikely to become a path to prevention. But the Warburg revival has allowed researchers to develop a hypothesis for how the diets that are linked to our obesity and diabetes epidemics — specifically, sugar-heavy diets that can result in permanently elevated levels of the hormone insulin — may also be driving cells to the Warburg effect and cancer.
The insulin hypothesis can be traced to the research of Lewis Cantley, the director of the Meyer Cancer Center at Weill Cornell Medical College. In the 1980s, Cantley discovered how insulin, which is released by the pancreas and tells cells to take up glucose, influences what happens inside a cell. Cantley now refers to insulin and a closely related hormone, IGF-1 (insulinlike growth factor 1), as “the champion” activators of metabolic proteins linked to cancer. He’s beginning to see evidence, he says, that in some cases, “it really is insulin itself that’s getting the tumor started.” One way to think about the Warburg effect, says Cantley, is as the insulin, or IGF-1, signaling pathway “gone awry — it’s cells behaving as though insulin were telling it to take up glucose all the time and to grow.” Cantley, who avoids eating sugar as much as he can, is currently studying the effects of diet on mice that have the mutations that are commonly found in colorectal and other cancers. He says that the effects of a sugary diet on colorectal, breast and other cancer models “looks very impressive” and “rather scary.”
Elevated insulin is also strongly associated with obesity, which is expected soon to overtake smoking as the leading cause of preventable cancer. Cancers linked to obesity and diabetes have more receptors for insulin and IGF-1, and people with defective IGF-1 receptors appear to be nearly immune to cancer. Retrospective studies, which look back at patient histories, suggest that many people who develop colorectal, pancreatic or breast cancer have elevated insulin levels before diagnosis. It’s perhaps not entirely surprising, then, that when researchers want to grow breast-cancer cells in the lab, they add insulin to the tissue culture. When they remove the insulin, the cancer cells die.
“I think there’s no doubt that insulin is pro-cancer,” Watson says, with respect to the link between obesity, diabetes and cancer. “It’s as good a hypothesis as we have now.” Watson takes metformin for cancer prevention; among its many effects, metformin works to lower insulin levels. Not every cancer researcher, however, is convinced of the role of insulin and IGF-1 in cancer. Robert Weinberg, a researcher at M.I.T.’s Whitehead Institute who pioneered the discovery of cancer-causing genes in the ’80s, has remained somewhat cool to certain aspects of the cancer-metabolism revival. Weinberg says that there isn’t yet enough evidence to know whether the levels of insulin and IGF-1 present in obese people are sufficient to trigger the Warburg effect. “It’s a hypothesis,” Weinberg says. “I don’t know if it’s right or wrong.”
During Warburg’s lifetime, insulin’s effects on metabolic pathways were even less well understood. But given his ego, it’s highly unlikely that he would have considered the possibility that anything other than damaged respiration could cause cancer. He died sure that he was right about the disease. Warburg framed a quote from Max Planck and hung it above his desk: “A new scientific truth does not triumph by convincing its opponents and making them see the light, but rather because its opponents eventually die.”
It is a long read. I put it aside & almost forgot about it.
Mention of Warburg tends to make me wary. The people who spread the myths that cannot be stopped often use his name.
And it's easy to see how even a piece like the one above can be misunderstood:
"sugar-heavy diets that can result in permanently elevated levels of the hormone insulin"
"Cantley, who avoids eating sugar as much as he can ... says that the effects of a sugary diet on colorectal, breast and other cancer models “looks very impressive” and “rather scary.”
Blood glucose comes from carbohydrate. The fate of digestible carbohydrate is to end up as glucose. The glycemic index [GI] of glucose is set as 100. Sucrose (which is what we think of as 'sugar') is a conjugate of fructose & glucose. It has to be broken up before glucose can enter the blood. The conversion of fructose to glucose is slow - the GI of fructose is only 25. The GI of sucrose is 65 - less than the GI of white bread (75). White rice is 73. Brown rice is 68.
I wish that people would stop saying 'sugar' when they mean 'glucose'. Perhaps they would then stop blaming table sugar. The glycemic load [GL] takes serving size into account. GL of sucrose (2 tsp) is only 6. The GL of boiled white rice (1 cup) is 35.
The subject of Warburg & glycolysis tends to be a distraction in PCa, since cells mostly use fatty acids (particularly palmitic acid), yet many men report that they have given up sugar.
The use of Metformin does not starve cancers of glucose, of course, since doctors are not trying to make patients hypoglycemic. Cancers that need glucose take what they need.
But, by eliminating glucose spikes, insulin sensitivity might be restored & over-production might stop. The importance of insulin as a PCa growth factor is made evident by the fact that long-term diabetics have less PCa than non-diabetics, & that this is the only cancer for which this is so.
Oh, I see you take it as a supplement...I was interested in cooking with red yeast...I will check out the pill form on the excellent results you report....it’s a funny thing but I’ve developed high cholesterol and with a shift over to more of the bad....I only had it checked once when I was an edurance athlete and I remember a rather eye popping hdl.....so my doctor said...not so now. Does PC actually change one’s cholesterol profile...sounds far fetched....despite we love to blame it for everything spare speeding tickets.
Don't mean to alarm but zytiga is antgonistic to cyp17A1 liver enzyme....this DOESNT act globally for ALL cytochrome functions which is one hell of a yoeman involved in many of the liver's full detoxifying spectrum...as well as our discussed cholesterol disynthesis and other sterol conversions..It merits further inspection...One might conclude that your liver enzyme tests should reflect anything destructive happening...so no foul no harm. You've been my perfect test trialer buddy...and it looks like we're good to go. I jumped the gun....zytiga is very monofocal...it only blocks DHEA production.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Keytruda and brain tumors
Cavernous Tumor & Rising PSA
Proton therapy with tumor against recrum
Boron Inhibits Tumor-induced Angiogenesis
LU-177 clinical trial and nueroendocrine tumors
